MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness (FuncProst)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Oslo University Hospital
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
Therese Seierstad, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01464216
First received: October 31, 2011
Last updated: October 20, 2014
Last verified: October 2014

October 31, 2011
October 20, 2014
October 2011
December 2015   (final data collection date for primary outcome measure)
Death [ Time Frame: 2030 ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01464216 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate cancer aggressiveness.

A prospective study including 180 consecutive patients with PCa referred to Oslo University Hospital, Radiumhospitalet, for surgical treatment. In vivo functional MRI examination will be performed within a few days prior to robot-assisted radical prostatectomy (RALP). A subgroup of high-risk patients (D'Amico risk classification) will prior to surgery receive an intravenous infusion of the hypoxia-marker pimonidazole (Hypoxyprobe™-1). During surgery, bone marrow aspiration and blood collection will be performed for assessment of disseminated and circulating tumor cells. High-risk patients will undergo intraoperative lymph node dissection. Tumor tissue for molecular analyses will be sampled from prostate specimen prior to fixation. Prostate specimen and regional lymph nodes will be histopathologically examined for T- and N-classification, Gleason grade, presence of micrometastasis and areas of hypoxia. Histological and molecular findings will be correlated to MRI findings and clinical data. Patients will be longitudinally followed to assess long-time clinical outcome (recurrence, metastatic disease, death).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood, bone marrow, lymph nodes, prostate tissue

Non-Probability Sample

Prostate cancer patients referred for surgical treatment.

  • Prostatic Neoplasms
  • Genital Neoplasms, Male
  • Prostatic Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
December 2030
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3
  • Patient has received no prior treatment for prostate cancer.
  • Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute.
  • Patient must sign written informed consent according to the protocol approved by the Regional Ethics Committee.

Exclusion Criteria:

  • Patient with contraindication to MR or MR contrast media according to clinical practice.
  • Patients who want to withdraw for any reason during the study.
  • Patients previously undergone pelvic surgery or radiation therapy
Male
Not Provided
No
Contact: Therese Seierstad, PhD, MHA therese@radium.uio.no
Norway
 
NCT01464216
REK-2010/1656
No
Therese Seierstad, Oslo University Hospital
Oslo University Hospital
Radboud University
Not Provided
Oslo University Hospital
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP